New research was reported in the journal Arthritis and Rheumatism that shows glucosamine and chondroitin for arthritis treatment are no better than placebo in slowing the loss of knee cartilage. The two-year study showed that the popular over the counter supplements did not work better than sugar pills.
Arthritis Pain Treatment
Researchers from Brigham and Women’s Hospital (BWH) and colleagues have uncovered specific locations on chromosomes (loci) linked to rheumatoid arthritis (RA), a progressive autoimmune disease that attacks the joints and other organs. Variations in the genetic sequence at these locations imply a risk of developing RA.
A new study in the New England Journal of Medicine shows that arthroscopic surgery with debridement to "clean up" an arthritic knee was of no more benefit than Advil or Tylenol and physical therapy in men and women with osteoarthritis. The same findings were reported in 2002 in a large study done by the Department of Veterans Affairs, but orthopedic surgeons have continued performing the surgery as a treatment for chronic knee pain in patients with osteoarthritis.
Osteoarthritis patients do not really benefit from arthroscopic surgery, which is a common treatment method for knee patients.
Knee patients suffering from osteoarthritis usually experience pain and weakened joint function. They are being treated by physical therapy, medication, and arthroscopic surgery. This surgery is not very invasive - a small arthroscope (long, thin, fiberoptic tube) and a few other instruments are being inserted into the joint. The instruments remove cartilage fragments and make joint surfaces smoother. The surgery is easy to perform and is widely acceptable.
About 1 in 5 Utah adults have doctor-diagnosed arthritis. Now, a new Utah Department of Health (UDOH) report shows many of them also have other conditions that add to their health care challenges.
Emotional and physical limitations are significant challenges cited by people diagnosed with rheumatoid arthritis (RA), according to the results released today from two new, groundbreaking parallel surveys.
Updated rules add new arthritis drugs and combinations for treatment. However, these recommendations for rheumatoid arthritis treatment are not meant to override individualized care.
Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB).
Health Canada is advising consumers not to use 3rd Generation In Homoeopathy Arthrit Indica Tablet due to concerns about possible side-effects.
Product label promotes use for "intense joint pain."
Arthrit Indica Tablets contain nimesulide, a pharmaceutical ingredient that is not authorized for sale in Canada. Nimesulide has been withdrawn from the market in several countries due to an association with liver damage.
Use of nimesulide has been associated with liver damage.
Researchers have found that a gene region known to play a role in some varieties of adult rheumatoid arthritis is also present in all types of childhood arthritis. The researchers say the responsible gene may be a "master switch" that helps turn on the debilitating disease.
Seven-year rheumatoid arthritis data from open-label extension studies show that treatment with Abbott's HUMIRA resulted in clinical remission among long-standing RA patients when used in combination with methotrexate.
Patients who suffer the chronic and debilitating effects of rheumatoid arthritis achieved significant improvements in signs and symptoms when treated with Roche's ACTEMRA alone or in combination with methotrexate compared with methotrexate alone.
New data suggest that patients with osteoarthritis pain of the knee treated with 60 mg and 120 mg Cymbalta once daily experienced significant pain reduction.
Patients receiving every four-week subcutaneous injections of golimumab 50 mg and 100 mg and weekly methotrexate experienced significant improvements in the signs and symptoms of rheumatoid arthritis.
Patients with moderately-to-severely active rheumatoid arthritis who were previously treated with anti-tumor necrosis factor-alpha agents, experienced significant improvements in signs and symptoms and physical function after receiving every four-week subcutaneous injections of golimumab.
We have too few pediatric rheumatologists in the United States, but this is not the only problem in the delay or inacurrate diagnosis of juvenile rheumatoild arthritis (JRA).
Arthritis affects one in every four adults in Wisconsin, and nationally it is the most common cause of disability. Yet state health officials report that if arthritis sufferers exercise for short periods of time, despite their discomfort, they can come one step closer to relieving some of their aches and pains.
More than half of adults with diagnosed diabetes also have arthritis, a painful condition that can be a barrier to physical activity-an important health strategy for managing diabetes.
Wyeth Pharmaceuticals has commenced patient dosing in the next Phase 2b clinical trial of TRU-015 in patients with rheumatoid arthritis (RA). In collaboration with Trubion, Wyeth Pharmaceuticals is developing TRU-015, SBI-087 and other CD20-directed products.
Physical Activity is Vital for Successful Management of Both Arthritis and Diabetes.
Wyeth Pharmaceuticals has initiated a Phase 1 clinical trial of SBI-087, a next-generation drug candidate for the treatment of rheumatoid arthritis (RA). In collaboration with Trubion, Wyeth Pharmaceuticals is developing SBI-087 and other CD20-directed products. SBI-087 for RA builds on Trubion and Wyeth's clinical experience with Trubion's lead compound, TRU-015, and is based on Trubion's Small Modular ImmunoPharmaceutical (SMIP) technology.
Study assessed the association between decline-to-fill rates as they relate to out-of-pocket expense for members initiating TNF-blocker therapy for the treatment of inflammatory conditions such as rheumatoid arthritis.
More than 20 million Americans suffer from osteoarthritis, with half a million Americans having a total joint replacement each year. A new study to be published in the April 2008 edition (Volume 22, issue No 4) of the journal of Phytotherapy Research shows Pycnogenol (pic-noj-en-all), an antioxidant plant extract from the bark of the French maritime pine tree, was shown to reduce all osteoarthritis symptoms by 56 percent. The study revealed a particularly high efficacy of Pycnogenol for lowering joint pain by 55 percent.
Abbott has received approval from the Japanese Ministry of Health, Labour and Welfare for HUMIRA for the treatment of rheumatoid arthritis in patients with inadequate response to conventional therapy.
FDA has approved Bristol-Myers Squibb's ORENCIA for reducing signs and symptoms in pediatric patients six years and older with moderately to severely active polyarticular juvenile idiopathic arthritis.
Common genetic variants linked to arthritis may also play a role in human height.
About 294,000 U.S. children and teenagers under age 18 (or one in 250 children) have been diagnosed with arthritis or another rheumatologic condition.